Readministration of abciximab in percutaneous coronary intervention

Journal of Invasive Cardiology

Volumn 11, Issue 4, 1999, Pages 251-258

  Fry, Edward T A ^a  

^a ST VINCENT HOSPITAL   (United States)

Author keywords

Allergy; GP inhibitors; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HUMAN; RETREATMENT; REVIEW; RISK; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETREATMENT; RISK; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0001255608     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
2. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT-II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996;78(Suppl 3A):35-40.
3. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-484.